The FDA said in a statement that it had determined that one of the two approved vaccines, Ixchiq (Valneva SE), which contains a live, weakened version of the chikungunya virus, was responsible for 21 ...

The FDA suspends Ixchiq, the only approved chikungunya vaccine, over safety concerns, impacting its availability in the U.S.

In a U-turn from a decision two weeks ago, the FDA – citing new safety events – said the vaccine is a "danger to health".

According to the vaccine's maker, Valneva, the FDA based its decision to suspend the shot on four new serious adverse events ...

A detail of a packaging of the Ixchiq chikungunya vaccine, in a pharmacy in Saint-Denis, La Réunion, is shown March 21. The ...

Center for Biologics Evaluation and Research (CBER) has suspended the biologics license for Valneva’s Ixchiq (Chikungunya ...

HealthDay News — The US Food and Drug Administration (FDA) is suspending the biologics license for the live-attenuated chikungunya vaccine, Ixchiq, in the United States. The move comes after reports ...

Valneva must immediately cease U.S. shipments and sales of Ixchiq, a vaccine for chikungunya virus. The FDA recently lifted a ...

FDA suspends Ixchiq license, raising regulatory risks for Valneva. Key vaccines anchor revenue, but valuation concerns emerge ...

Mainland France has seen an explosion of chikungunya outbreaks this summer and local officials are hunting down the tiger mosquitoes responsible for spreading the virus. Meanwhile, the United States ...

Worrisome new signals caused the U.S. FDA – which earlier this month OK’d revised labeling for Valneva SE’s chikungunya virus ...

The agency said it had become aware of more reports of serious adverse events, leading center director Vinay Prasad to ...